Investigating the Pharmacognostic Potential of Indian Terminalia Spp. in the Treatment and Prevention of Yersiniosis


Pharmacognosy Communications,,2017,7,3,108-113.
Published:September 2017
Type:Original Article

Investigating the Pharmacognostic Potential of Indian Terminalia Spp. in the Treatment and Prevention of Yersiniosis

Mitchell Henry Wright,a Anthony Carlson Greene,b Ian Edwin Cock,b,c*

aDivision of Environmental and Biomolecular Systems, Institute of Environmental Health, Oregon Health & Science University, Portland, Oregon, USA.

bSchool of Natural Sciences, Griffith University, Nathan Campus, Queensland, AUSTRALIA.

cEnvironmental Futures Research Institute, Nathan Campus, Griffith University, 170 Kessels Rd, Nathan, Queensland 4111, AUSTRALIA.


Introduction: Yersinia enterocolitica is a major cause of food poisoning through contaminated meat products, causing the acute gastrointestinal disease yersiniosis. Many Terminalia spp. have documented therapeutic properties as general antiseptics, inhibiting the growth of a wide variety of bacterial species. Despite this, Indian Terminalia spp. extracts have not been tested for the ability to inhibit the growth of Y. enterocolitica. Methods: T. arjuna, T. catappa and T. chebula extracts were extracted by maceration and the extracts were investigated by disc diffusion assay for growth inhibitory activity against a clinical strain of Y. enterocolitica. The MIC values of the extracts were determined to quantify and compare their efficacies. Toxicity was determined using the Artemia franciscana nauplii bioassay. Results: T. chebula fruit extracts displayed potent growth inhibitory activity in the disc diffusion assay against Y. enterocolitica. The methanolic and ethyl acetate T. chebula fruit extracts were particularly potent growth inhibitors, with MIC values of 85 and 64 μg/mL respectively. The aqueous fruit extract also displayed good growth inhibitory activity against Y. enterocolitica, albeit with a higher MIC value (653 μg/mL). The T. arjuna branch extract was moderately active (3000 μg/mL). All other extracts were either low efficacy, or completely devoid of growth inhibitory activity. All Indian Terminalia spp. extracts were nontoxic (LC50 values <1000 μg/mL) in the Artemia franciscana bioassay. Conclusions: The lack of toxicity and the potent growth inhibitory bioactivity of the T. chebula extracts against Y. enterocolitica indicates their potential as medicinal agents in the treatment and prevention of yersiniosis.

Founded:  In 2004, as the PHCOG.NET – a non-profit private organization dedicated to Natural Products Research leading to develop promising drugs. Our main mission is to make information on herbal drug research readily available in different formats to suit the individual needs.

Pharmacognosy Communications [Phcog Commn.] is a new quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the  publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.

The journal aims to cater the latest outstanding developments in the field of pharmacognosy and natural products and drug design covering but not limited to the following topics:

  • Pharmacognosy and pharmacognistic investigations
  • Research based ethnopharmacological evaluations
  • Biological evaluation of crude extracts, essential oils and pure isolates
  • Natural product discovery and evaluation
  • Mechanistic studies
  • Method and technique development and evaluation
  • Isolation, identification and structural elucidation of natural products
  • Synthesis and transformation studies

Distinctions:  The most widely read, cited, and known Pharmacognosy Communications and website is well browsed with all the articles published. More than 20,000 readers in nearly every country in the world each month

Aim and Scope | Editorial Board | Indexed & Abstracted | Instruction to Authors | Manuscript Submission & Charges

Subjects Covered : Natural Products, Pharmacognosy, Phytochemistry, Marine Pharmacognosy and Zoo Pharmacognosy
ISSN :2249-0159 (Print) ; 2249-0167 (Online) Frequency : Quarterly Rapid at a time publication (4 issues/year)

Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online  publication is 45 days.
Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.